Porton Pharma Solutions Ltd. (300363.SZ)
CNY 15.02
(0.74%)
CNY 15.02
(0.74%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 639.82 Million CNY | -74.34% |
| 2022 | 2.53 Billion CNY | 213.36% |
| 2021 | 762.73 Million CNY | 51.3% |
| 2020 | 520.93 Million CNY | 42.35% |
| 2019 | 354.47 Million CNY | 23.55% |
| 2018 | 320.29 Million CNY | 7.68% |
| 2017 | 279.88 Million CNY | -21.57% |
| 2016 | 323.6 Million CNY | 63.83% |
| 2015 | 215.77 Million CNY | 2.82% |
| 2014 | 191.87 Million CNY | 41.09% |
| 2013 | 144.68 Million CNY | 14.74% |
| 2012 | 123.97 Million CNY | 32.14% |
| 2011 | 96.44 Million CNY | 26.07% |
| 2010 | 76.29 Million CNY | 37.29% |
| 2009 | 60.83 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.13 Million CNY | 80.14% |
| 2024 Q3 | -35.38 Million CNY | -335.02% |
| 2024 Q1 | -123.58 Million CNY | 16.55% |
| 2023 Q4 | -49.07 Million CNY | -1201.88% |
| 2023 Q1 | 318.04 Million CNY | -42.61% |
| 2023 Q3 | 4.45 Million CNY | -96.19% |
| 2023 Q2 | 116.8 Million CNY | -63.27% |
| 2023 FY | - CNY | -74.34% |
| 2022 Q2 | 1.03 Billion CNY | 134.06% |
| 2022 FY | - CNY | 213.36% |
| 2022 Q4 | 554.17 Million CNY | 93.34% |
| 2022 Q3 | 286.63 Million CNY | -72.4% |
| 2022 Q1 | 443.72 Million CNY | 104.44% |
| 2021 FY | - CNY | 51.3% |
| 2021 Q1 | 102.56 Million CNY | 1.79% |
| 2021 Q4 | 217.04 Million CNY | 32.86% |
| 2021 Q3 | 163.35 Million CNY | 9.59% |
| 2021 Q2 | 149.05 Million CNY | 45.34% |
| 2020 FY | - CNY | 42.35% |
| 2020 Q4 | 100.75 Million CNY | -19.53% |
| 2020 Q3 | 125.2 Million CNY | -2.07% |
| 2020 Q2 | 127.85 Million CNY | 118.85% |
| 2020 Q1 | 58.42 Million CNY | -17.17% |
| 2019 Q3 | 93.28 Million CNY | 21.52% |
| 2019 Q4 | 70.52 Million CNY | -24.39% |
| 2019 FY | - CNY | 23.55% |
| 2019 Q1 | 25.5 Million CNY | -48.79% |
| 2019 Q2 | 76.76 Million CNY | 201.03% |
| 2018 Q2 | 89.52 Million CNY | 1533.03% |
| 2018 FY | - CNY | 7.68% |
| 2018 Q4 | 49.79 Million CNY | -38.38% |
| 2018 Q3 | 80.8 Million CNY | -9.74% |
| 2018 Q1 | -6.24 Million CNY | -114.54% |
| 2017 Q1 | 79.95 Million CNY | -24.83% |
| 2017 FY | - CNY | -21.57% |
| 2017 Q4 | 42.97 Million CNY | 28.87% |
| 2017 Q3 | 33.35 Million CNY | 214.38% |
| 2017 Q2 | 10.6 Million CNY | -86.73% |
| 2016 Q3 | 33.04 Million CNY | -52.09% |
| 2016 Q2 | 68.98 Million CNY | -2.54% |
| 2016 Q4 | 106.37 Million CNY | 221.87% |
| 2016 FY | - CNY | 63.83% |
| 2016 Q1 | 70.78 Million CNY | 2.13% |
| 2015 FY | - CNY | 2.82% |
| 2015 Q4 | 69.3 Million CNY | 127.58% |
| 2015 Q3 | 30.45 Million CNY | -36.99% |
| 2015 Q2 | 48.33 Million CNY | 71.35% |
| 2015 Q1 | 28.2 Million CNY | -64.76% |
| 2014 Q2 | 24.93 Million CNY | -37.13% |
| 2014 Q1 | 39.66 Million CNY | 338.99% |
| 2014 FY | - CNY | 41.09% |
| 2014 Q4 | 80.04 Million CNY | 128.45% |
| 2014 Q3 | 35.03 Million CNY | 40.53% |
| 2013 Q2 | 18.2 Million CNY | -68.08% |
| 2013 FY | - CNY | 14.74% |
| 2013 Q1 | 57.02 Million CNY | 0.0% |
| 2013 Q3 | 49.76 Million CNY | 173.36% |
| 2013 Q4 | 9.03 Million CNY | -81.84% |
| 2012 FY | - CNY | 32.14% |
| 2011 FY | - CNY | 26.07% |
| 2010 FY | - CNY | 37.29% |
| 2009 FY | - CNY | 0.0% |